Formulation and Evaluation of Transdermal Patches of Meloxicam
Shaikh Muzammil Shaikh Laal1*, S.A. Bhagat2, Sayyad Toufik Agamiyan3,
S.B. Jadhav4, V.V. Navghare5
1,3Research Scholar, Department of Pharmaceutics, Indira College of Pharmacy,
Vishnupuri, Nanded, Maharashtra Pin: 431606, India.
2,4,5Assistant Professor, Department of Pharmaceutics, Indira College of Pharmacy,
Vishnupuri, Nanded, Maharashtra Pin: 431606, India.
*Corresponding Author E-mail: sshaikhmuzammil20@gmail.com
ABSTRACT:
The present research work focused on the formulation and evaluation of Meloxicam transdermal patches for sustained drug delivery in the treatment of inflammatory conditions and pain. Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), is associated with gastrointestinal irritation and first-pass metabolism following oral administration. To overcome these limitations, transdermal patches were prepared by the solvent casting method using varying ratios of HPMC K15M and Ethyl Cellulose along with PEG 400, glycerin, and oleic acid. FTIR studies confirmed the compatibility of Meloxicam with the selected excipients. Six formulations (F1–F6) were prepared and evaluated for physicochemical parameters such as thickness, weight variation, drug content, folding endurance, surface pH, swelling index, and in vitro drug release. All formulations showed smooth and uniform films with satisfactory mechanical properties and drug distribution. Drug content ranged from 97.85 ± 1.18% to 99.68 ± 0.98%. The surface pH was near neutral, indicating suitability for skin application. The in vitro drug release study demonstrated that the polymer ratio significantly affected drug release behavior. Among all formulations, F5 was identified as the optimized batch, showing 98.85 ± 1.60% cumulative drug release over 24 hours with sustained release characteristics. Drug release kinetics revealed that F5 best fitted the Higuchi model, indicating diffusion-controlled drug release. Stability studies confirmed the physical and chemical stability of the optimized formulation under accelerated conditions. The study concluded that, the developed Meloxicam transdermal patches, particularly formulation F5, exhibited satisfactory physicochemical properties, sustained drug release, and good stability, indicating their potential as an effective transdermal drug delivery system.
KEYWORDS: Meloxicam, HPMC, Ethyl Cellulose, Solvent Casting etc.
INTRODUCTION:
Oral administration of drugs is commonly frequently most widely utilized route for administering pharmaceutical agents, but it is associated with several limitations, including pre-systemic hepatic metabolism and enzymatic breakdown in the alimentary canal, along with variability in drug uptake due to pH changes. To overcome these limitations, alternative drug administration approaches have become developed, of these skin-based drug delivery systems have gained recognition as an effective and increasingly important drug delivery strategy1,2. TDDS utilizes medicated adhesive patches formulated to provide a controlled specified amount of the drug through cutaneous absorption into systemic circulation. These systems consist of various components and are applied to intact skin, where drug permeation occurs through the accessory appendages via different anatomical components of the skin, including hair follicles, oil-producing glands, and sweat ducts and stratum corneum, ultimately enabling systemic drug delivery. Transdermal systems are widely employed for the management of conditions such as angina pectoris, pain, smoking cessation, Parkinson’s disease, and several other disorders1.
Meloxicam specifically targets and inhibits cyclooxygenase-2 (COX-2) and is extensively prescribed for treating rheumatoid arthritis and osteoarthritis, including other inflammatory diseases because of its strong pain-relieving, inflammation-reducing, and antipyretic effects. Nevertheless, its oral administration is restricted by its low aqueous solubility, inconsistent gastrointestinal absorption, as well as the potential to gastric irritation. Transdermal delivery offers an effective alternative by bypassing gastrointestinal barriers, maintaining stable plasma drug levels, reducing dosing frequency, and minimizing systemic side effects.
In the current study, Meloxicam-loaded transdermal patches are formulated and assessed using suitable polymeric systems to achieve optimized drug release and enhanced skin permeation. Polymeric film-forming materials such as a utilizing ethyl cellulose (EC) together with polyvinyl pyrrolidone (PVP) are utilized to obtain desirable mechanical strength, flexibility, and controlled release characteristics. Plasticizers like polyethylene glycol (PEG) are incorporated to improve elasticity and handling properties of the patch. This investigation aimed to was designed to design a stable, effective and patient-compliant transdermal drug delivery system for improved clinical effectiveness of Meloxicam3,4.
MATERIALS AND METHODS:
A complimentary sample of Meloxicam was provided by Cipla Limited, Mumbai. Ethyl Cellulose and Hydroxypropyl methylcellulose (HPMC) K15M was obtained from S. D. Fine Chemicals. The remaining solvents and all reagents used were of analytical grade.
Formulation of Meloxicam Transdermal Delivery System:
Meloxicam-loaded patches were fabricated using the solvent casting technique along with a combination of HPMC K15M and ethyl cellulose, representing hydrophilic and hydrophobic polymers, respectively, in varying proportions as per the formulation design. HPMC K15M was first dispersed n distilled water while being continuously stirred and left for hydration for 4–6 hours to ensure complete swelling and removal of entrapped air bubbles. In a separate vessel, ethyl cellulose was dissolved in ethanol under continuous stirring to achieve a clear polymeric solution. Both polymeric phases were then combined gradually with constant stirring to form a uniform polymer matrix.
A accurately weighed quantity of Meloxicam (85mg per patch basis) was dissolved in ethanol and slowly embedded in the polymer matrix blend while stirring continuously to achieve homogeneous drug dispersed in polymer matrix. Plasticizers such as polyethylene glycol (PEG 400) along with glycerin were incorporated to increase the flexibility of the prepared film, while oleic acid was included to act as a permeation enhancer for improving drug diffusion via the skin. Final mixture was continuously stirred thoroughly to obtain a clear, uniform, and bubble-free casting solution.
The prepared solution was cast onto a clean, smoothed, pre-lubricated glass Petri dish and cast evenly. The Solvent evaporation under ambient conditions for 24 hours resulting in a thin, flexible membrane. Once dried, the patches were gently removed, examined for uniformity, and cut into required size 2 × 2cm² sizes, each containing approximately 85 mg of Meloxicam. Finally, the formulated patches were enclosed within aluminum foil and placed kept inside a desiccator for storage prior to subsequent evaluation5,6,7. The formulation details are presented in Table 1.
Table 1: Formulation Composition of Meloxicam Transdermal Patches
|
Ingredients (mg) |
F1 |
F2 |
F3 |
F4 |
F5 |
F6 |
|
Meloxicam |
85 |
85 |
85 |
85 |
85 |
85 |
|
HPMC K15M |
300 |
250 |
200 |
150 |
100 |
50 |
|
Ethyl Cellulose |
50 |
100 |
150 |
200 |
250 |
300 |
|
PEG 400 |
80 |
80 |
80 |
80 |
80 |
80 |
|
Glycerin |
40 |
40 |
40 |
40 |
40 |
40 |
|
Oleic Acid |
20 |
20 |
20 |
20 |
20 |
20 |
|
Solvent (Water: Ethanol) |
q.s. |
q.s. |
q.s. |
q.s. |
q.s. |
q.s. |
Evaluation of Transdermal Patches:
1. Physical Characteristics:
The developed drug-loaded skin patches were subjected to visual inspection to assess their appearance in terms of color, clarity, surface smoothness, flexibility, and overall uniformity8,9. Each patch was observed against a uniform background to identify any surface imperfections such as air bubbles and cracks, crystallization of drug, and phase separation. The transparency or opacity and homogeneity of the film surface were also assessed. A smooth, uniform, and defect-free film was considered to indicate good film-forming ability and acceptable formulation quality8.
2. Thickness of the Patch:
The thickness of the formulated transdermal patches was assessed by employing calibrated micrometer at different locations on each patch. Measurements were taken from multiple points to ensure uniformity and consistency of the prepared films. The average thickness was calculated and reported as the mean value, which served as an indicator of the reproducibility and quality of the formulation10,11.
3. Weight Variation:
The developed transdermal patches underwent drying at 60°C for 4 h before to evaluation to remove any residual moisture. Patches of the same dimensions were selected randomly and the weight of each patch was determined using a digital analytical balance. The average weight and standard deviation was computed to assess uniformity and reproducibility of the prepared patches12,13,14.
4. Drug Content:
A 2 × 2cm² section of the patch was dissolved in a mixture of chloroform and methanol. The solution was kept in a shaker for 24 hours with continuous agitation to ensure the drug was completely extracted. The resulting solution was subsequently filtered, and drug content was examined by employing a spectrophotometry at 360 nm15.
5. Folding Endurance:
The measured folding endurance of the formulated patches was assessed by repeatedly bending the patch at the same point until it fractured or showed visible cracking. The folding count of the film could withstand with no damage was noted16,17. This test evaluates the mechanical strength as well as the flexibility of the patch, where greater folding endurance indicates superior elasticity and resistance to brittleness16,18.
6. Surface pH Assessment:
The measured pH at the surface of the formulated therapeutic patches were evaluated to determine the interaction within the dermal layer and to assess the likelihood of irritation after application. For this reason, the patches were allowed to undergo swelling in a small amount of distilled water for a defined time period. The pH of the surface was then recorded using a pre-calibrated using an electronic pH meter by carefully placing the electrode kept in contact with the surface of the swollen membrane. The readings were taken for each individual formulation and the calculated mean value was found. A pH of the surface approximately close towards the physiological skin pH (around 5.5–7.0) indicated good compatibility and suggested minimal risk of skin irritation, confirming suitability for transdermal delivery19.
7. Moisture Uptake (%):
The transdermal patches were accurately weighed and stored in a moisture-controlled desiccator using saturated potassium chloride solution employed to ensure a relative humidity of approximately 84%. The fabricated patches were stored at ambient temperature for 24 h and subsequently reweighed. The moisture percentage uptake was estimated from that variation between the the pre- and post-weights, which reflects the moisture-absorbing capacity in the formulated patches20,21,22.
% Absorption of Moisture = [(Final Wt. − Initial Wt.) / Initial Wt.] × 100
8. Moisture Loss (%):
The percentage moisture loss observed in the formulated transdermal patches were determined by assessing the reduction in weight after storage under dry conditions. Accurately weighed patches were maintained in a desiccator filled with calcium chloride (anhydrous form) and maintained at the specified temperature for 24 h. Upon the specified duration, the formulated patches were weighed once again, and the moisture content (%) was computed from the distinction between the pre- and post- weights23,24,25.
% Moisture Loss = (W1 -W2)/(W1) X 100
W₁ = Initial weight of the formulated transdermal patch (mg)
W₂ = Weight of the transdermal patch post-drying (mg)
9. Swelling Study:
the swelling capacity of the prepared transdermal patches was examined through initially weighing each patch (W1) and then incubating them at 37±0.5°C on a 2% agar gel medium. At regular time intervals of 15 minutes up to 1hour, the patches were carefully withdrawn, as well as the residual surface moisture was meticulously absorbed via means of filtering medium (paper-based). The water-swollen patches were thereafter subsequently reweighed (W₂). The level of swelling behavior of the sample was determined by the measured swelling index using the standard formula26.
Swelling Index (%) = (W2 -W1)/(W1) X 100
10. In Vitro Release of Drug Analysis:
The in vitro release of the drug study profile in the formulated transdermal patches was analyzed utilizing a Franz diffusion cell comprising donor and receptor chambers with a suitable membrane placed between them. The receptor compartment was filled with an appropriate diffusion and maintained kept at 37±0.5°C with the aid of a thermostatically controlled water jacket. The medium was kept continuously stirred with a a magnetic stirring device to achieve uniform drug dispersion throughout the investigation. At specified intervals sampling intervals, aliquots were periodically collected from the receptor compartment and refilled via an equivalent amount freshly prepared medium to ensure sink conditions. The obtained experimental samples were examined utilizing a suitable analytical technique, and the cumulative percentage drug release was determined27,28,29,25.
11. Study of Kinetics of Drug Release:
The observations derived from the in vitro release profile of the drug were processed utilizing various mathematical models for determine the drug release behavior mechanism. The optimal-fitting model was observed to describe the release mechanism and behavior of associated with drug release from the developed patches30,31.
12. Stability Studies:
the stability characteristics of developed formulation medicated transdermal patches was performed under various storage conditions to determine their physical and chemical stability over the course of a specified duration of time. The formulated patches were hermetically sealed in aluminum foil and stored under appropriate conditions at ambient (25–30°C/60% RH) and accelerated (45–50°C/75% RH) conditions for during a span of 0 days. Samples were withdrawn at predetermined intervals (days 0, 15, 30, 45, 60, and 90), and evaluated the drug content as well as other relevant physicochemical parameters. The obtained results were compared to determine the stability of the formulations during storage32.
RESULTS AND DISCUSSION:
Preformulation Studies:
Melting Point Determination:
The Fusion process of Meloxicam was recorded employing a capillary tube method and was recorded in the range of 258–260°C. The measured value was comparable with the reported pharmacopoeial range, reflecting the quality and authenticity of the active pharmaceutical ingredient (API) substance.
Solubility Studies:
The aqueous solubility profile of Meloxicam was assessed in several solvents, and the findings derived are shown in Table 2.
Table 2: Solubility Evaluation of Meloxicam in Different Solvents
|
Sr No |
Solvents |
Solubility |
|
1 |
Water |
Insoluble |
|
2 |
Methanol |
Slightly soluble |
|
3 |
Ethanol |
Soluble |
|
4 |
DMSO |
Soluble |
|
5 |
Dichloromethane |
Soluble |
|
6 |
Acetone |
Slightly soluble |
UV Spectroscopy (Determination of λmax):
A solution of 10µg/mL of Meloxicam within phosphate buffer solution (pH 7.4) was determined within a wavelength range of 200–800nm a UV spectrophotometer. The absorption maximum (λmax) was measured at 360nm, in agreement with the reported value.
Figure 1: Absorption Maxima (λ max) of Meloxicam at 360 nm
Compatibility Studies (FT-IR):
The FT-IR spectrum of Meloxicam showed characteristic absorption bands relating to its major functional groups, with a broad absorption band appearing in the 3200–3400 cm⁻¹ region was attributed associated with N–H stretching vibrations, while peaks observed the band the maximum at 2920–2850 cm⁻¹ corresponded to aliphatic C–H stretching. Furthermore, the characteristic peak around 1650 m⁻¹ was recorded to carbonyl (C=O) stretching of the amide group. Furthermore, absorption bands in the spectral range of 1550–1500 cm⁻¹, 1450–1400 cm⁻¹ along with 1100–1000 cm⁻¹ were assigned to C–N stretching, aromatic C=C, and S=O stretching vibrations, respectively. These findings were consistent with the reported standard spectrum of Meloxicam, confirming its identity and structural integrity.
The FT-IR spectral analysis of the physical mixture containing Meloxicam, HPMC in combination with ethyl cellulose retained all major characteristic peaks of the drug substance. No major shift, loss, or emergence of newly detected peaks were observed, confirming non-appearance of the chemical interaction among Meloxicam and the selected polymers. These results confirmed the compatibility of Meloxicam with HPMC and ethyl cellulose for transdermal patch formulation. FT-IR spectral analysis of the pure Meloxicam and the drug–polymer blend physical mixture are illustrated in Figures 2 and 3, respectively.
Figure 2: FT-IR Spectra of Pure Drug Meloxicam
Figure 3: FT-IR Spectra of Meloxicam with Ethyl Cellulose and HPMC K15M
Standard Calibration Curve of Meloxicam:
A series of Meloxicam solutions within the range of 2–12 µg/mL were made in phosphate-buffered medium maintained at pH 7.4 from the formulated stock solution and analyzed at maximum wavelength (λmax) (360 nm) employing a UV spectrophotometer. The absorbance data obtained plotted versus concentration, and the data were applied to linear regression analysis. The calibration curve revealed good linearity within the studied concentration range, with absorbance increasing proportionally with drug concentration. This demonstrated compliance with Beer–Lambert’s law. The absorbance data and corresponding calibration curve are illustrated in Table 3 and Figure 4, respectively.
Table 3: Standard Calibration Curve of Meloxicam in Phosphate Buffer Solution (pH 7.4)
|
Sr. No |
Concentration (µg/ml) |
Absorbance |
|
0 |
0 |
0 |
|
1 |
2 |
0.179 |
|
2 |
4 |
0.324 |
|
3 |
6 |
0.454 |
|
4 |
8 |
0.618 |
|
5 |
10 |
0.784 |
|
6 |
12 |
0.936 |
Figure 4: Calibration Curve of Meloxicam in Phosphate Buffer Solution (pH 7.4)
Evaluation of Transdermal Patches:
The developed Meloxicam-loaded transdermal patches (F1–F6) were examined for physicochemical properties, including (physical appearance, patch film thickness, weight variation, drug content uniformity, folding endurance, and surface pH, moisture uptake (%) uptake, and moisture loss (%)). The obtained results revealed that all formulations exhibited satisfactory physicochemical properties. Furthermore, the ratio of the hydrophilic polymer (HPMC) present in combination with lipophilic polymer (ethyl cellulose) significantly influenced the overall properties and performance of the transdermal drug delivery patches.
Physical Characteristics:
All the formulated transdermal patches were subjected to visual evaluation for appearance, transparency, as well as consistency. The films were obtained to be smooth, homogeneous, and exhibited no visible imperfections such as air bubbles, visible cracks, or surface imperfections, indicating successful film formation by the solvent casting method. Formulation F1 exhibited higher transparency, which may be attributed to the greater proportion of HPMC and its excellent film-forming properties. In contrast, formulation F6 appeared slightly opaque because of the higher ethyl cellulose concentration, a hydrophobic polymer known to produce less transparent films.
Film Thickness, Weight Variation, and Drug Content Uniformity:
The film thickness of the patch formulated transdermal patches fell within the range of 0.24±0.01mm to 0.29± 0.02mm, indicating uniform film formation. A slight increase in thickness was observed across formulations F1 to F6, which may be ascribed owing towards the higher amount of ethyl cellulose in the formulations. Uniform thickness is essential for maintaining consistent drug distribution and release characteristics.
The weight variation of the patches (2 × 2cm²) ranged from 198.45±1.22mg to 208.85±1.40mg. The observed increase in patch weight from F1 to F6 was associated with the increasing proportion of ethyl cellulose. the relatively low standard deviation values indicated homogeneous distribution throughout the formulation components and reproducibility of the casting process.
The drug content uniformity fell within the varying from 97.85±1.18% to 99.68±0.98%, indicating homogeneous dispersion of Meloxicam throughout the polymer matrix. whereas the low variability among formulations confirmed efficient drug incorporation and homogeneity. Among all formulations, F5 exhibited the highest drug content (99.68±0.98%), suggesting optimal drug dispersion within the polymer matrix. The obtained results are presented in Table 4 and Figure 5.
Figure 5: Percentage Drug Content of Meloxicam Transdermal Patch (F1 to F6)
Folding Endurance:
Folding endurance is an important parameter that reflects the mechanical properties and flexibility of transdermal patches, that are essential convenient handling, storage, and patient acceptability. The observed folding endurance values of the developed Meloxicam patch formulations ranged from 135±4.25 to 195±5.40, indicating adequate flexibility of all formulations. A gradual increase in folding endurance was observed ranging from F1 to F6, which can be explained by the increasing proportion of ethyl cellulose polymer that enhanced the mechanical properties of the films. Formulation F1 exhibited comparatively lower folding endurance, whereas F6 showed the highest value. Among all formulations, F5 demonstrated an optimum folding endurance value of 188±5.25, indicating a suitable balance between flexibility and mechanical strength for effective application. The obtained results are presented in Table 4 and Figure 6.
Figure 6: Folding Endurance values of Meloxicam Transdermal Formulation F1 to F6
Surface pH, Moisture Uptake (%) and Moisture Loss (%):
The pH of the patch surface prepared transdermal patch values varied from 6.32±0.08 to 6.85±0.07, which closely resembles the physiological pH of the skin. These values show that the formulations are non-irritant as well as suitable for transdermal use. Formulation F5 exhibited the recorded surface pH of 6.72±0.05, indicating good skin compatibility.
The percentage moisture uptake ranged from 6.85± 0.42% to 3.25±0.25%. A decreasing trend was observed the variations among F1 to F6 may be attributed to the increased concentration of the hydrophobic ethyl cellulose along with the decreasing proportion of hydrophilic HPMC polymer. Formulation F5 showed moderate moisture uptake (3.85±0.28%), indicating a suitable balance between flexibility and stability.
The percentage moisture loss fell within the range of 5.42±0.38% to 3.10±0.25%. Formulations containing higher amounts of HPMC exhibited greater moisture loss, whereas increasing ethyl cellulose concentration reduced moisture loss. Formulation F5 exhibited controlled moisture loss (3.52±0.28%), suggesting improved stability and reduced brittleness. Overall, all formulations showed acceptable moisture characteristics suitable for transdermal application.
Table 4: Comparative Evaluation Parameters of Meloxicam Transdermal Patches
|
Parameter |
F1 |
F2 |
F3 |
F4 |
F5 |
F6 |
|
Physical Appearance |
Smooth, transparent |
Smooth |
Smooth |
Smooth |
Smooth, flexible |
Slightly opaque |
|
Thickness (mm) |
0.24±0.01 |
0.25±0.01 |
0.26±0.01 |
0.27±0.01 |
0.28±0.01 |
0.29±0.02 |
|
Weight Variation (mg) |
198.45±1.22 |
200.36±1.28 |
202.18±1.30 |
204.65±1.35 |
206.42±1.25 |
208.85±1.40 |
|
Drug Content (%) |
97.85±1.18 |
98.42±1.12 |
98.95±1.10 |
99.12±1.05 |
99.68±0.98 |
98.76±1.15 |
|
Folding Endurance |
135±4.25 |
148±4.60 |
162±4.85 |
175±5.10 |
188±5.25 |
195±5.40 |
|
Surface pH |
6.32±0.08 |
6.45±0.07 |
6.58±0.06 |
6.64±0.06 |
6.72±0.05 |
6.85±0.07 |
|
% Moisture Uptake |
6.85±0.42 |
5.92±0.38 |
5.15±0.35 |
4.42±0.30 |
3.85±0.28 |
3.25±0.25 |
|
% Moisture Loss |
5.42±0.38 |
4.85±0.35 |
4.32±0.32 |
3.95±0.30 |
3.52±0.28 |
3.10±0.25 |
All values are mean±SD (n=3)
Swelling Study:
The swelling properties of the prepared transdermal films (F1–F6) was analyzed at specified time intervals (15, 30, 45, and 60min). Each formulation showed a gradual a steady rise in the swelling index with time, reflecting gradual hydration of the system absorption along with polymer hydration.
Among the prepared formulations, F1 exhibited the highest swelling index (145.82±1.76% at 60min), which may be due to its higher content of hydrophilic HPMC K15M with strong water absorption and gel-forming ability. Formulations F2 and F3 showed moderate swelling of 129.48±1.60% and 112.63±1.44%, respectively, due to the reduced proportion of HPMC and increased ethyl cellulose content.
A further decrease in swelling was observed in F4, F5, and F6, with F6 showing the lowest swelling index (63.15±1.06% at 60min). This reduction is attributed to the The greater amount of hydrophobic polymer (ethyl cellulose), which limits water penetration and polymer chain relaxation. Collectively, results suggest evealing that the swelling behavior is strongly governed by the ratio of hydrophilic and hydrophobic polymers. The obtained findings are presented in Table 5 and Figure7.
Figure 7: Swelling studies of Transdermal Patches of Meloxicam (F1 to F6)
In Vitro Drug Release Profile:
The in vitro release behavior of the drug analysis of Meloxicam transdermal patches (F1–F6) was conducted over 24hours using a diffusion-based system. The findings indicated that the drug was released profile was highly a function of the ratio of the hydrophilic polymer HPMC along with hydrophobic ethyl cellulose.
Formulation F1, which contained a higher proportion of HPMC, showed rapid drug release, exhibiting 18.45± 1.12% released within the first hour and nearly complete release (99.68±1.70%) by 12 hours. This faster release may be due to enhanced hydration, swelling, and pore formation caused by the hydrophilic nature of HPMC.
Formulations F2 to F4 exhibited progressively slower release patterns, reaching near-complete release between 16 and 20hours. This gradual retardation in drug release is mainly attributed to the increasing proportion of ethyl cellulose, which reduces water penetration and restricts drug diffusion through the matrix.
Formulation F5 demonstrated a well-controlled and sustained release profile over 24hours (98.85±1.60%), suggesting an optimal balance between HPMC and ethyl cellulose for extended drug delivery. In contrast, F6 showed the slowest release, with 85.42±1.55% drug release at 24hours, likely due to the dominance of ethyl cellulose forming a dense and less permeable matrix.
Collectively, the results suggest that polymer composition has a crucial role in controlling drug release behavior. HPMC enhances drug release through swelling and channel formation, whereas ethyl cellulose acts as a release-retarding agent by limiting diffusion. The release data of all formulations are shown in Table 6 and Figures 8.
Table 5: Swelling Studies of Transdermal Patches of Meloxicam
|
Time (min) |
F1 |
F2 |
F3 |
F4 |
F5 |
F6 |
|
15 |
68.45 ± 1.12 |
60.32 ± 1.05 |
52.18 ± 0.96 |
44.76 ± 0.88 |
36.54 ± 0.82 |
28.63 ± 0.75 |
|
30 |
95.28 ± 1.35 |
84.17 ± 1.22 |
72.45 ± 1.10 |
61.83 ± 1.02 |
50.72 ± 0.95 |
39.64 ± 0.88 |
|
45 |
121.64 ± 1.58 |
108.35 ± 1.41 |
93.82 ± 1.28 |
79.46 ± 1.16 |
64.58 ± 1.05 |
51.27 ± 0.97 |
|
60 |
145.82 ± 1.76 |
129.48 ± 1.60 |
112.63 ± 1.44 |
96.25 ± 1.32 |
78.94 ± 1.18 |
63.15 ± 1.06 |
All values are mean ± SD (n=3)
Table 6: In Vitro Release Analysis of Meloxicam-Loaded Transdermal Patch
|
Time (hrs) |
F1 |
F2 |
F3 |
F4 |
F5 |
F6 |
|
1 |
18.45 ± 1.12 |
14.32 ± 1.05 |
12.25 ± 1.08 |
10.12 ± 1.02 |
8.65 ± 0.98 |
6.42 ± 0.95 |
|
2 |
32.68 ± 1.25 |
28.45 ± 1.18 |
24.36 ± 1.20 |
20.85 ± 1.15 |
18.42 ± 1.10 |
14.28 ± 1.08 |
|
4 |
55.24 ± 1.40 |
48.32 ± 1.35 |
42.18 ± 1.30 |
38.56 ± 1.28 |
34.72 ± 1.22 |
28.95 ± 1.20 |
|
6 |
70.85 ± 1.52 |
63.42 ± 1.45 |
58.36 ± 1.40 |
52.78 ± 1.35 |
48.25 ± 1.30 |
40.68 ± 1.28 |
|
8 |
82.36 ± 1.60 |
75.18 ± 1.52 |
68.42 ± 1.48 |
62.35 ± 1.42 |
58.96 ± 1.38 |
50.42 ± 1.35 |
|
10 |
90.12 ± 1.65 |
84.36 ± 1.58 |
78.25 ± 1.52 |
72.48 ± 1.48 |
68.42 ± 1.42 |
58.36 ± 1.40 |
|
12 |
99.68 ± 1.70 |
90.45 ± 1.62 |
85.36 ± 1.58 |
80.25 ± 1.52 |
75.84 ± 1.48 |
65.42 ± 1.45 |
|
16 |
- |
98.82 ± 1.68 |
90.42 ± 1.62 |
89.38 ± 1.58 |
82.56 ± 1.52 |
72.35 ± 1.48 |
|
20 |
- |
- |
99.85 ± 1.68 |
97.45 ± 1.62 |
91.42 ± 1.58 |
80.28 ± 1.52 |
|
24 |
- |
- |
- |
- |
98.85 ± 1.60 |
85.42 ± 1.55 |
All values are mean±SD (n=3)
Figure 8: Comparative In-Vitro Drug Release Profile of Meloxicam Transdermal Patches Formulations F1 to F6
Kinetics of Drug Release:
The results obtained from in vitro release studies drug of Meloxicam transdermal patches (F1–F6) were assessed using different kinetic modeling approaches comprising the zero-order, first-order, Higuchi, and Korsmeyer–Peppas models were applied to elucidate the mechanism governing drug release from the polymeric matrix system. Evaluation of kinetic model fitting was carried out as per the regression coefficient of determination (R²) value, and release exponent (n) was used to determine the drug transport mechanism.
Across all formulations, F5 emerged as the optimized batch due to its balanced and sustained release profile. Gave best conformed to the Higuchi model provided the best fit (R² = 0.981), suggesting that drug release was observed to be mainly controlled by means of diffusion through the matrix system. The results obtained from the Korsmeyer–Peppas model value (n = 0.756) indicated an anomalous (non-Fickian) transport mechanism in which the combined effects drug release was governed by diffusion and polymer relaxation the overall the release profile of the drug. The findings suggest that that formulation F5 provides a controlled release behavior suitable for transdermal delivery.
Stability Studies:
The stability analysis of the optimized Meloxicam transdermal patch formulation (F5) was kept under accelerated storage conditions at 40°C for a duration of 90 days to evaluate alterations in physicochemical properties and drug release behavior. Key parameters, including folding endurance, drug content along with in vitro release profile of the drug, were compared prior towards and post the storage period.
The folding endurance showed a slight change from 188 ±5.25 to 190±4.74 after 90 days, indicating that the mechanical flexibility of the patch remained stable during storage. This stability may be due to the presence of plasticizers such as PEG 400 and glycerin, which help maintain elasticity and prevent brittleness.
Drug content demonstrated a minimal was reduced from 99.68±0.98% to 98.66±0.84%, which is within acceptable limits and suggests that Meloxicam remained stable within the polymer matrix without significant degradation. Similarly, the in vitro drug release remained almost unchanged, with values of 98.85±1.60% before storage and 99.14±1.63% after 90 days, indicating that the release characteristics were not influenced by storage conditions.
Collectively, the findings indicated that formulation F5 remained physically and chemically stable under accelerated conditions and maintains its performance over time The obtained data are presented in Table 8.
Table 7: Kinetic Model Fitting of Drug Release Profiles for Formulations F1–F6
|
Formulation |
Zero Order |
First Order |
Higuchi |
Korsmeyer-Peppas |
Best Fitting Model |
|
|
R2 |
R2 |
R2 |
R2 |
(‘n’ Value) |
|
|
|
F1 |
0.973 |
0.788 |
0.988 |
0.989 |
0.676 |
Peppas |
|
F2 |
0.965 |
0.931 |
0.983 |
0.977 |
0.700 |
Higuchi |
|
F3 |
0.815 |
0.804 |
0.979 |
0.971 |
0.700 |
Higuchi |
|
F4 |
0.813 |
0.957 |
0.982 |
0.976 |
0.756 |
Higuchi |
|
F5 |
0.819 |
0.909 |
0.981 |
0.969 |
0.756 |
Higuchi |
|
F6 |
0.808 |
0.996 |
0.979 |
0.966 |
0.807 |
First Order |
Table 8: Stability Study of Optimized Meloxicam Transdermal Patch Formulations F5 Stored at (400 C)
|
Evaluation Parameter |
Before Stability (0 Days) |
After Stability (90 Days) |
|
Folding Endurance |
188 ± 5.25 |
190 ±4.74 |
|
Drug Content |
99.68 ± 0.98 |
98.66 ±0.84 |
|
% Drug release |
98.85 ± 1.60 |
99.14±1.63 |
CONCLUSION:
The present study successfully developed Meloxicam transdermal patches utilizing the solvent casting technique with HPMC K15M and ethyl cellulose as polymeric carriers. FTIR studies established the compatibility of Meloxicam with the chosen excipients, showing no significant drug–polymer interaction.
All developed formulations (F1–F6) showed acceptable physicochemical properties such as uniform thickness and good folding endurance, satisfactory drug content, and suitable surface pH, indicating their suitability for transdermal delivery. Swelling studies and in vitro drug release evaluation confirmed that the polymer ratio is a major factor governing drug release.
Formulation F5 emerged since the optimized batch, indicating a balanced release profile with sustained drug delivery and good stability. Overall, the developed system showed potential as an effective transdermal drug delivery approach for Meloxicam, with improved patient compliance and prolonged therapeutic action. Additional in vivo studies are recommended to confirm its clinical performance and safety.
ACKNOWLEDGEMENTS:
I am deeply grateful to S.A. Bhagat for her advice and assistance during the writing of this research article. I am also appreciative to Indira College of Pharmacy, Vishnupuri Nanded, Maharashtra for giving me access to the books and resources I needed to complete this work.
CONFLICT OF INTEREST:
The authors declare no conflict of interest.
LIST OF ABBREVIATION:
|
API |
Active Pharmaceutical Ingredient |
|
COX-2 |
Cyclooxygenase-2 |
|
DMSO |
Dimethyl Sulfoxide |
|
EC |
Ethyl Cellulose |
|
FT-IR |
Fourier Transform Infrared Spectroscopy |
|
HPMC |
Hydroxypropyl Methylcellulose |
|
HPMC K15M |
Hydroxypropyl Methylcellulose K15M |
|
N |
Release Exponent (Korsmeyer–Peppas Model) |
|
NSAID |
Non-Steroidal Anti-Inflammatory Drug |
|
PEG |
Polyethylene Glycol |
|
PEG 400 |
Polyethylene Glycol 400 |
|
pH |
Potential of Hydrogen |
|
PVP |
Polyvinyl Pyrrolidone |
|
R² |
Coefficient of Determination |
|
RH |
Relative Humidity |
|
SD |
Standard Deviation |
|
TDDS |
Transdermal Drug Delivery System |
|
UV |
Ultraviolet Spectroscopy |
|
λmax |
Wavelength of Maximum Absorbance |
REFERENCES:
1. Kadam AS, Ratnaparkhi MP, Chaudhary SP. Transdermal drug delivery: An overview. Int J Res Dev Pharm L Sci. 2014; 3(4): 1042-1053.
2. Latheeshjlal L, Phanitejaswini P, Soujanya Y, Swapna U, Sarika V, Moulika G. Transdermal drug delivery systems: An overview. Int J Pharmtech Res. 2011; 3: 2140-2148.
3. Pathan IB, Setty CM. Chemical penetration enhancers for transdermal drug delivery systems. Trop J Pharm Res. 2009; 8(2): 173-179.
4. Patel PM, Bhaskar VH. In-vitro, Ex-vivo Skin Permeation and Biological Evaluation of 18-β Glycyrrhitic Acid Transdermal Patches. Int. J Pharm Res Rev. 2015; 4(8): 28-36.
5. Sanap GS, Dama GY, Hande AS, Karpe SP, Nalawade SV, Kakade RS. Preparation of transdermal monolithic systems of indapamide by solvent casting method and the use of vegetable oils as permeation enhancer. Int J Green Pharm 2008; 2: 129-33.
6. Murthy TEGK, Kishore VS. Effect of casting solvent on permeability of antihypertensive drugs through ethyl cellulose films. J Sci Ind Res 2008; 67: 147-50.
7. Mehdizadeh A, Toliate T, Rouini MR, Abashzadeh S, Dorkoosh F. Design and in vitro evaluation of new drug-in-adhesive formulations of fentanyl transdermal patches. Acta Pharm 2004; 54: 301–17.
8. Gupta JRD., Irchhiaya R., Garud N., Tripathi P. Formulation and Evaluation of Matrix Type Transdermal Patches of Glibenclamide. International Journal of Pharmaceutical Sciences and Drug Research. 2009: 1(1):46-50.
9. Ragni Kumari, Virendra Kumar Sharma. Optimization of the Formulation of Transdermal patches of Amiodarone. Research Journal of Pharmacy and Technology. 2023; 16(8): 3739-2. DOI: 10.52711/0974-360X.2023.00617
10. Keleb E, Sharma RK, Mosa EB, Aljahwi A-AZ. Transdermal Drug Delivery System- Design and Evaluation. International Journal of Advances in Pharmaceutical Sciences. 2010; 1:201-211.
11. Patel DM, Kavitha K. Formulation and Evaluation Aspect of Transdermal Drug Delivery System. Int Jour of Pharm Sci Review and Res. 6.
12. Levin G, Gershonowitz A, Sacks H, Stern M, Sherman A, Rudaev S, Zivin I, Phillip M, Transdermal delivery of human growth hormone through RF microchannels, PharmRes, 2005,22(4),550-5.
13. Sivakumar T, Selvam PR, Singh AK, Transdermal drug delivery systems for antihypertensive drugs - A review. Int J Pharm Biomed Res. 2010; 1, 1-8.
14. Reddy RK, Muttalik S, Reddy S. Once daily sustainedrelease matrix tablets of nicorandil: formulation and in vitro evaluation. AAPS. Pharm. Sci. Tech. 2003; 4: 4.
15. Afzal, S.; Barkat, K.; Ashraf, M.U.; Khalid, I.; Mehmood, Y.; Shah, N.H.; Badshah, S.F.; Naeem, S.; Khan, S.A.; Kazi, M. Formulation and Characterization of Polymeric Cross-Linked Hydrogel Patches for Topical Delivery of Antibiotic for Healing Wound Infections. Polymers. 2023; 15: 1652.
16. Saeed, S.; Barkat, K.; Ashraf, M.U.; Shabbir, M.; Anjum, I.; Badshah, S.F.; Aamir, M.; Malik, N.S.; Tariq, A.; Ullah, R. Flexible Topical Hydrogel Patch Loaded with Antimicrobial Drug for Accelerated Wound Healing. Gels 2023; 9: 567.
17. Babu GD, Kantipotu CS, Bhoot MS, Adhikarla PS, Rao NVB. Design and Evaluation of Valsartan Transdermal Patches. IJRAP 2012; 3(3).
18. Ananda PW, Elim D, Zaman HS, Muslimin W, Tunggeng MG, Permana AD. Combination of transdermal patches and solid microneedles for improved transdermal delivery of primaquine. International Journal of Pharmaceutics. 2021; 609: 121204. DOI: 10.1016/j.jpharm.2021.121204
19. Nishad KM, Arul B, Rajasekaran S. Design and comparative evaluation of clarithromycin gastric bioadhesive tablets by ex vivo and in vivo methods. Asian J Pharm Clin Res 2018; 11:248–56.
20. J. Ashok Kumar, Nikhila Pullakandam, S. Lakshmana Prabu, V. Gopal., Transdermal Drug Delivery System: An Overview. 2010; 3(2): 49-54.
21. Sachin B. Jadhav, Ankita R. Koshti, M.M Bari, S.D. Barhate. Formulation optimization and Evaluation of Transdermal Patch of Losartan Potassium containing DMSO as permeation enhancer. Asian J. Pharm Tech. 2019; 9(3): 220-227. DOI: 10.5958/2231-5713.2019.00037.0
22. Ismail Hussain, Ravikumar, Narayanaswamy VB, Injamamul Haque, Mohibul Hoque. Design and Evaluation of Transdermal Paches containing Risperidone. Asian J. Res. Pharm. Sci. 2016; 4: 208-222.doi: 10.5958/2231-5659.2016.00030.8
23. Mohammadpoor SA, Akbari S, Sadrjahani M, Nourpanah P. Fabrication of electrospun ibuprofen-loaded poly (vinyl alcohol)/ hyper-branched poly(ethylenimine) fibers and their release behaviors. Journal of Biomaterials Science-Polymer Edition. 2020 Jan; 31(2): 261–275.
24. Wiedersberg S, Guy RH. Transdermal drug delivery: 30+ years of war and still fighting! Journal of Controlled Release. 2014; 190:150-6. doi.org/10.1016/j.jconrel.2014.05.022
25. Kumar K, Nida P. Development of nanoparticles of an antifungal drug incorporated in transdermal patch. Research Journal of Pharmacy and Technology. 2023; 16(5): 2125-32. doi.org/ 10.52711/0974-360X.2023.00349
26. Sridhar BK, Wahid A, Shivakumar S. Preparation and evaluation of transdemal drug delivery system of etoricoxib using modified chitosan. Indian J Pharm Sci. 2008; 70(4): 455-60.
27. Patel D, Chaudhary SA, Parmar B, Bhura N. Transdermal drug delivery system: A review. Pharma Innov. 2012; 1: 78-87.
28. Hardainiyan S, Kumar K. Design, Formulation and in vitro Drug Release from Transdermal Patches containing Nebivolol Hydrochloride as Model Drug. Asian J. Pharm. Res. 2012; 2(4): 136-141.
29. Himani Bajaj, Seema Bisht Chauhan, Mayank Yadav, Navin Chandra Pant, Mamta Farswan Singh, Vinod Singh. Non-Aqueous Based HPMC Transdermal Patch of Aceclofenac: In vitro characterization. Research Journal of Pharmacy and Technology. 2024; 17(3): 1107-3. DOI: 10.52711/0974-360X.2024.00173.
30. Domenech J, Cordero JA, Alarcon L, Escribano E. A comparative study of the transdermal penetration of a series of nonsteroidal antiinflammatory drugs. J Pharm Sci. 2000; 86(4): 503-8.
31. Zhonggui He, Yu Liu, Liang fang, Haifa Zheng, Ligang Zhao, Xinyu Ge. Development and in-vitro evaluation of a topical use patch containing diclofenac diethenolamine salt. Asian Journal of Pharmaceutical Sciences. 2007; 2(3):106-13.
32. Shah SS, Joshi R, Prabhakar P. Formulation and evaluation of transdermal patches of Papaverine hydrochloride. Asian Jour of Pharm. 2010.
|
Received on 01.07.2026 Revised on 18.08.2026 Accepted on 19.09.2026 Published on 15.10.2026 Available online from October 24, 2026 Res. J. Pharma. Dosage Forms and Tech.2026; 18(4):281-290. DOI: 10.52711/0975-4377.2026.00039 ©AandV Publications All Right Reserved
|
|
|
This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License. |
|